Contact Us: 1-888-667-3325 /

Subscriber Content Preview | Request a free trialSearch  


Spinout from Ventas-Ardent REIT deal in final auction stages

Private equity firms are interested in the operating company, which could bring in upward of $500 million in a sale. Continue reading

Drugstore operator CVS Health acquires pharmacy benefits manager Omnicare for $12.7B

The purchase provides an entry for CVS into the rapidly growing senior care space. Continue reading

China Inc. goes private -- one mediocre piece at a time

Beijing's restructuring of state-owned enterprises will generate some opportunities for foreign investors, but in a seller's market the government is always looking out mainly for itself. Continue reading

Pfizer invests in Dutch kidney drug developer AM-Pharma

The New York drugs maker has started with a minority investment, but has the option to buy the company and its potential drug for up to $600 million. Continue reading

Syngenta lets Monsanto approach wither, says offer is too low, complicated

The Swiss crop chemicals company may still be a target after its board rejects the $45 billion takeover proposal. Continue reading

For Teva, poison pills and regulatory worries won't stop the march on Mylan

The generics giant's offer is contingent on the target dropping its own offer for Perrigo, which right now will be a tough sell to its shareholders. Continue reading

Antitrust protections no 'road map' for merger challenges, regulators say

Common fear that merger agreement covenants will tip off officials to competitive harms called unfounded. Continue reading

Mylan bids $29B for generics drug company Perrigo in latest big pharma deal

The bid, made public under Irish law, provides for $205 per share for Perrigo's stock. Continue reading

Novartis makes history and the biosimilar industry looks even more attractive

Pfizer, Teva and Actavis are potential consolidators, while Momenta, Coherus and Epirus lead the list of likely targets. Continue reading

Concordia Healthcare acquires Covis Pharma for $1.2B in cash

Concordia picks up 18 drugs in acquisition of PE-backed Covis, as big deals in the pharmaceuticals space continue. Continue reading

Piercing the once-impregnable steel veil at dual-share companies

Insurgents are finding ways to apply pressure, especially where the nature of the ownership is depressing stock prices. Continue reading

Three companies benefiting from Obamacare's expanded access to mental health services

The law made access to treatment for addiction and other problems widely available. More patients with the means to pay for care is creating greater opportunities for providers. Continue reading

Meet the journalists

William Blair's Dan Shedivy sits down to talk M&A in the healthcare services sector

Middle Market healthcare deals stayed strong in 2014 but were relative ... Video

More Healthcare video

The Deal's Webcast Series

If you have not had the chance to enjoy our Webcast Series, now is the time. Join these free 60-minute discussions and get a handle on the latest strategies and tactics in private equity, cross-border and middle market dealmaking and more.

Industry Events

View information on all upcoming industry events which The Deal representatives are participating in.

The Deal Economy Event

The Deal’s senior journalists host the industry's leading M&A forecasting event, an invitation-only gathering of influential members of the deal community discussing the outlook for dealmaking in the coming year.

The Deal on Twitter

Follow @TheDealNewsroom for the latest news across mergers and acquisitions, auctions, financings, restructurings and more!